Every week, Rinchem shares important articles and topics about chemical and gas logistics, industries we operate in, and the general global supply chain. In this week's update we talk about news from the Virginia Port, restructuring of South Korea's petrochem market, and a new FDA program meant to boost production.
Keep reading to see this week's hot topics.
This week's stats
$1.4 Billion- Investments for modernization and infrastructure improvements for the Port of Virginia Transportation & Logistics International
10- Number of petrochemical firms that agreed to reduce capacity in South Korea ICIS
Over 50%- The percentage of all pharmaceuticals distributed in the U.S. sourced from overseas BioProcess International
Virginia strengthens its position as a supply chain powerhouse
Virginia is cementing its role as a pivotal supply-chain nexus on the East Coast by leveraging its prime coastal geography and modernizing its port infrastructure. The Port of Virginia sits at the heart of these efforts, backed by over $1.4 billion in upgrades through its Gateway Investment Program to deepen shipping channels, deploy new rail-mounted gantry cranes, and enhance cargo velocity—including improvements at the Richmond Marine Terminal and Virginia Inland Port—resulting in notable gains in efficiency and rail capacity. Combined with the support of expanding road, rail, and distribution infrastructure, these enhancements are transforming Virginia into a faster, more resilient hub for domestic and international freight movement.
South Korea’s Petchem Restructuring: Challenges and Opportunities
South Korea’s petrochemical sector is undergoing a critical transformation driven by a prolonged downturn triggered by China’s self-sufficiency push and global overcapacity. In response, ten leading firms have committed to cutting naphtha-cracking capacity by 2.7 to 3.7 million tonnes per year—up to 25% of the national total—while shifting their business models from commodity-focused to higher-value, eco-friendly products. This restructuring initiative, framed as “self-rescue first, government support second,” requires companies to submit detailed plans by the end of 2025 to qualify for financial, tax, and regulatory incentives. The government also intends to designate “industrial crisis zones” (such as possibly Seosan) to help cushion economic and job losses in affected regions.
FDA’s PreCheck program seeks to supercharge US domestic drug production
The U.S. Food and Drug Administration (FDA) has launched the PreCheck program, aimed at revitalizing domestic pharmaceutical manufacturing by streamlining regulatory pathways for building new drug production facilities. Implemented in response to Executive Order 14293, the initiative employs a two-phase strategy: the "Facility Readiness Phase" fosters early and frequent dialogue between manufacturers and the FDA during site planning and construction, while the "Application Submission Phase" focuses on pre-application meetings and early feedback to smooth the Chemistry, Manufacturing, and Controls (CMC) section of regulatory submissions. This effort addresses growing national security concerns over America’s heavy reliance on foreign drug production and seeks to bolster a more resilient domestic supply chain. Details will be further outlined at a public session in September at the FDA White Oak campus.
Get more articles like this in your inbox
Sign up for our monthly newsletter
Find more articles
Request a Quote
